NDC 68001-329

Bloxiverz

Neostigmine Methylsulfate

Bloxiverz is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Bluepoint Laboratories. The primary component is Neostigmine Methylsulfate.

Product ID68001-329_e024e2b9-5c3c-4ecb-a1d4-a7743baaebaa
NDC68001-329
Product TypeHuman Prescription Drug
Proprietary NameBloxiverz
Generic NameNeostigmine Methylsulfate
Dosage FormInjection
Route of AdministrationINTRAVENOUS
Marketing Start Date2017-06-30
Marketing CategoryNDA / NDA
Application NumberNDA204078
Labeler NameBluePoint Laboratories
Substance NameNEOSTIGMINE METHYLSULFATE
Active Ingredient Strength1 mg/mL
Pharm ClassesCholinesterase Inhibitor [EPC],Cholinesterase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 68001-329-67

10 CARTON in 1 PACKAGE (68001-329-67) > 1 VIAL, MULTI-DOSE in 1 CARTON (68001-329-66) > 10 mL in 1 VIAL, MULTI-DOSE
Marketing Start Date2017-06-30
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 68001-329-66 [68001032966]

Bloxiverz INJECTION
Marketing CategoryNDA
Application NumberNDA204078
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-06-30

NDC 68001-329-67 [68001032967]

Bloxiverz INJECTION
Marketing CategoryNDA
Application NumberNDA204078
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-06-30

Drug Details

Active Ingredients

IngredientStrength
NEOSTIGMINE METHYLSULFATE1 mg/mL

OpenFDA Data

SPL SET ID:84e9a534-dce6-4224-b65d-5404176b0103
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1429284
  • 311936
    • UPC Code
  • 0368001329675

    • Pharmacological Class

    • Cholinesterase Inhibitor [EPC]
    • Cholinesterase Inhibitors [MoA]
    • Cholinesterase Inhibitor [EPC]
    • Cholinesterase Inhibitors [MoA]

    NDC Crossover Matching brand name "Bloxiverz" or generic name "Neostigmine Methylsulfate"

    NDCBrand NameGeneric Name
    51754-1210BloxiverzNeostigmine Methylsulfate
    51754-1220BloxiverzNeostigmine Methylsulfate
    51754-1240Bloxiverzneostigmine methylsulfate
    68001-329BloxiverzBloxiverz
    76014-002BloxiverzBloxiverz
    76014-902BloxiverzBloxiverz
    76014-003BloxiverzBloxiverz
    76014-903BloxiverzBloxiverz
    0404-9925NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
    0517-1133Neostigmine MethylsulfateNeostigmine Methylsulfate
    0517-1134Neostigmine MethylsulfateNeostigmine Methylsulfate
    0548-9601NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
    0548-9602NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
    0641-6149Neostigmine MethylsulfateNeostigmine Methylsulfate
    0641-6150Neostigmine MethylsulfateNeostigmine Methylsulfate
    0641-6240Neostigmine MethylsulfateNeostigmine Methylsulfate
    14445-413NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
    14445-414NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
    23155-517Neostigmine MethylsulfateNeostigmine Methylsulfate
    23155-518Neostigmine MethylsulfateNeostigmine Methylsulfate
    25021-610Neostigmine MethylsulfateNeostigmine Methylsulfate
    25021-611Neostigmine MethylsulfateNeostigmine Methylsulfate
    31722-994neostigmine methylsulfateneostigmine methylsulfate
    31722-995neostigmine methylsulfateneostigmine methylsulfate
    42023-188NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
    42023-189NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
    43598-945Neostigmine MethylsulfateNeostigmine Methylsulfate
    50090-4532NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate
    50090-5197Neostigmine methylsulfateNeostigmine methylsulfate
    51662-1557NEOSTIGMINE METHYLSULFATENEOSTIGMINE METHYLSULFATE
    52584-057NEOSTIGMINE METHYLSULFATEneostigmine methylsulfate

    Trademark Results [Bloxiverz]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    BLOXIVERZ
    BLOXIVERZ
    85686242 4433582 Live/Registered
    Éclat Pharmaceuticals, LLC
    2012-07-25
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.